Onychomycosis (Tinea Unguium) Pipeline Review, H1 2019 Therapeutics Report - ResearchAndMarkets.com

The "Onychomycosis
(Tinea Unguium) - Pipeline Review, H1 2019" drug pipelines has
been added to ResearchAndMarkets.com's offering.

Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2019, provides
comprehensive information on the therapeutics under development for
Onychomycosis (Tinea Unguium) (Infectious Disease), complete with
analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.

The Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide
also reviews of key players involved in therapeutic development for
Onychomycosis (Tinea Unguium) and features dormant and discontinued
projects. The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in Phase
III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2,
7, 2, 2, 1 and 1 respectively.

Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide helps
in identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Onychomycosis (Tinea Unguium) (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Onychomycosis
  (Tinea Unguium) (Infectious Disease) by companies and
  universities/research institutes based on information derived from
  company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Onychomycosis
  (Tinea Unguium) (Infectious Disease) therapeutics and enlists all
  their major and minor projects.
• The pipeline guide evaluates Onychomycosis (Tinea Unguium) (Infectious
  Disease) therapeutics based on mechanism of action (MoA), drug target,
  route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease)

Companies Mentioned

• Almirall SA
• Blueberry Therapeutics Ltd
• Hexima Ltd
• Kaken Pharmaceutical Co Ltd
• Meiji Seika Pharma Co Ltd
• Moberg Pharma AB
• NAL Pharmaceuticals Ltd
• Novabiotics Ltd
• Novan Inc
• Viamet Pharmaceuticals Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/v91ngn

View source version on businesswire.com: https://www.businesswire.com/news/home/20190523005414/en/